The p53 tumour suppressor is frequently inactivated in human tumours. One form of inactivation results from overexpression of MDM2, that normally forms a negative auto-regulatory loop with p53 and inhibits its activity through complex formation. We have investigated whether disrupting the MDM2-p53 complex in cells that overexpress MDM2 is sucient to trigger p53 mediated cell death. We ®nd that expression of a peptide homologue of p53 that binds to MDM2 leads to increased p53 levels and transcriptional activity. The consequences are increased expression of the downstream eectors MDM2 and p21
The p53 tumour suppressor is frequently inactivated in human tumours. One form of inactivation results from overexpression of MDM2, that normally forms a negative auto-regulatory loop with p53 and inhibits its activity through complex formation. We have investigated whether disrupting the MDM2-p53 complex in cells that overexpress MDM2 is sucient to trigger p53 mediated cell death. We ®nd that expression of a peptide homologue of p53 that binds to MDM2 leads to increased p53 levels and transcriptional activity. The consequences are increased expression of the downstream eectors MDM2 and p21
, inhibition of colony formation, cell cycle arrest and cell death. There is also a decrease in E2F activity, that might have been due to the known physical and functional interactions of MDM2 with E2F1/DP1. However, this decrease is p53 dependent, as are also colony formation, cell cycle arrest and cell death. These results show that a peptide homologue of p53 is sucient to induce p53 dependent cell death in cells overexpressing MDM2, and support the notion that
Introduction
The p53 tumour suppressor has a key role in the protection against tumour formation and faulty development (reviews: Morgan and Kastan, 1997; Hollstein et al., 1997; Hansen and Oren, 1997; Levine, 1997; Wang and Harris, 1997; Almog and Rotter, 1997; Hall and Lane, 1997) . p53 regulates cell cycle progression and apoptosis in response to cellular stresses such as: DNA damage (Kastan et al., 1991) , faulty spindle formation (Minn et al., 1996) , depletion of oxygen (Graeber et al., 1996; An et al., 1998) , diminution in ribonucleotides (Linke et al., 1996) , transcription abnormalities (Andera and and teratogens (Wubah et al., 1996; Nicol et al., 1995) . p53 regulates the transcription of downstream eectors, such as the cyclin dependent kinase inhibitor p21 WAF1/CIP1 (p21) and the oncoprotein MDM2 (reviews: Piette et al., 1997; Momand and Zambetti, 1997; Haines, 1997) . MDM2 forms a complex with p53, inhibits its ability to activate transcription, and stimulates its degradation by the ubiquitin pathway (Lane and Midgley and Lane, 1997; Haupt et al., 1997; Kubbutat et al., 1997) . MDM2 down-regulation of p53 is critically important. During embryonic development, inactivation of the mdm2 gene results in a lethality that can be rescued by inactivation of the p53 gene (Montes de Oca Luna et al., 1995; Jones et al., 1995) . Tumour suppression by ARF-INK4a involves neutralisation of MDM2 mediated inhibition of p53 Pomerantz et al., 1998) . Inappropriate overexpression of MDM2 results in p53 inactivation and tumorigenesis. However, MDM2 has p53 independent functions, notably in cell cycle control and differentiation.
MDM2 interacts physically and functionally with several regulators of the cell cycle, including pRb (Xiao et al., 1995) , E2F1/DP1 (Martin et al., 1995) , p107 (Dubs-Poterszman et al., 1995) and CCG1 (LeÂ veillard and Wasylyk, 1997) . In transgenic animals and in the absence of p53, MDM2 overexpression in the mammary gland leads to uncontrolled entry into S phase and polyploidy (Lundgren et al., 1997) and overexpression in the skin results in hyper-proliferation and inhibition of dierentiation (Alkhalaf et al., 1998) . In cell culture, MDM2 inhibits muscle cell dierentiation and Myo-D dependent transactivation (Fiddler et al., 1996) . MDM2 also interacts with the ribosomal protein L5 and RNA , leading to the suggestion that MDM2 may regulate protein translation. The oncogenic properties of MDM2 in cell culture depend upon both p53 dependent (Finlay, 1993; Kondo et al., 1996) and independent (Dubs-Poterszman et al., 1995) mechanisms. Both properties may be important in human tumours. Simultaneous mutation of p53 and overexpression of MDM2 has been considered to be relatively rare (Florenes et al., 1994) , suggesting that they are functionally equivalent. However, concomitant p53 mutation and MDM2 overexpression gives a worst prognosis (Cordon-Cardo et al., 1994; Wurl et al., 1998) , showing that they are not completely redundant. Moreover, some carcinomas express MDM2 proteins that cannot interact with p53 but can transform cells in culture (Sigalas et al., 1996) .
The p53-MDM2 protein complex is potentially a target for the development of therapeutic agents for tumours expressing MDM2 and wild type p53. The p53-MDM2 regulatory circuit is fundamentally important in regulating the apoptotic properties of p53 (Kondo et al., 1995; Chen et al., 1996 Chen et al., , 1998 Haupt et al., 1996; Shaulian et al., 1997) . Furthermore, the structure of the p53-MDM2 complex has been determined (Kussie et al., 1996) . Small molecule inhibitors of the complex that bind to MDM2 would be expected to disrupt the p53-MDM2 complex, liberating p53 that could initiate the apoptotic program to kill the tumour cell. However, other considerations raise concerns as to whether disrupting the complex would be sucient. For example, high level MDM2 expression may decrease p53 to very low levels which are below a threshold required to initiate apoptosis. The p53 independent properties of MDM2 may outweigh the importance of p53 inactivation in cellular transformation. Phosphorylation of MDM2 may inhibit its ability to down-regulate p53 (Mayo et al., 1997) . We studied the eects of disrupting the p53-MDM2 complex in SA1 cells, that contain wild-type p53 and overexpress MDM2 due to gene ampli®cation. We report that a peptide homologue of p53 that binds to MDM2 (Bottger et al., 1996) leads to p53 dependent death. These results show that blocking the interaction of MDM2 with p53, without additional treatments, is sucient to kill transformed cells expressing high levels of MDM2.
Results

Tumour cell lines
Five cell lines were chosen for study ( Table 1) , four that express wild-type p53 (SA1, (Oliner et al., 1992) ); MCF7 (Midgley and Lane, 1997; Casey et al., 1991) ; CASK1 (Schener et al., 1991); HeLa (Yaginuma and Westphal, 1991) and one lacking p53 (Sakai and Tsuchida, 1992) . p53 is deregulated, by MDM2 overexpression in SA1 and E6 expression in CASKI and HeLa cells. p53 transcriptional activity, as measured in transfection assays using either lipofectamine or calcium phosphate and various reporters, was highest in SA1 and MCF7, much lower in CASKI and HeLa and undetectable in HSC2 (Table 1) . Western blots (Figure 1) showed that p53 protein levels are highest in MCF7 followed by SA1, lower in CASKI and below the level of detection in HeLa and HSC2. MDM2 is highest in SA1 followed by MCF7, with a lower level in HSC2 followed by CASKI and HeLa. These results show that there is detectable p53 transcriptional activity in SA1 cells despite the high levels of MDM2. p53 transcriptional activity can only be roughly correlated with its level of expression in dierent cell types.
p53 activity in SA1 cells is expected to be restrained by MDM2 overexpression and the MDM2 autoregulatory loop. To explore this possibility, we compared inhibition of colony formation by p53 with CTS1, a chimeric p53 molecule (Conseiller et al., 1998) . CTS1 is resistant to inactivation by MDM2 since it has the VP16 activation domain in the place of the p53 activation domain that interacts with MDM2. CTS1 has a similar activity to p53 in cells with low levels of MDM2, such as SAOS2. Expression vectors for p53 and CTS1 were cotransfected with a G418 selectable marker and, after selection in G418, the number of colonies were counted (Table 2 ). p53 had no eect, whereas CTS1 decreased colony formation about eightfold. Somewhat similarly, p53 was found to be much less eective than CTS1 in inhibition of the cell cycle (FACS analysis, data not shown). Of ®ve The oncogenic modi®cations in relation to p53 are mdm2 gene ampli®cation in SA1 and expression in E6 in CASKI and HeLa. Endogenous p53 activity was assessed by transfection with either lipofectamine or calcium phosphate and p53 reporters MDM2-luc, WAF1-luc and pCON-luc. Basal activity was measured by either expressing inhibitors of p53 (MDM2, HPV16 E6 and mutant p53) or with reporters lacking a response element (pGUP-luc). Endogenous p53 activity is highest in SA1 (+++) and MCF7 (++), followed by CASKI (+) and HeLa (+/7). There was no detectable activity (7) in HSC2 randomly picked p53 transfected colonies, three were found to express higher levels of p53 than the parent line. One of the clones was analysed further and was found to express a higher level of MDM2 (data not shown). These results can be interpreted in terms of the MDM2 autoregulatory loop model, in that forced expression of p53 could result in increased expression of MDM2 and restraint of p53 activity by MDM2 inhibition.
Expression of IP3, an inhibitor of MDM2 interaction with p53, is deleterious to survival of SA1 cells
We studied how inhibiting MDM2-p53 interactions would aect p53 activity in cells containing dierent levels of MDM2. We used IP3, a peptide developed by Lane and collaborators, that has been shown to eciently compete for p53 binding to MDM2 (Bottger et al., 1996) . We expressed IP3 as a fusion protein with GST, which is commonly used as a`tag' for protein expression in various cells. The eects were compared of IP3, a dimer of IP3 (IP3.2), a mutant IP3 (mIP3) with alanine substitutions of critical amino acids (Bottger et al., 1996) , and the GST tag alone. We initially studied the eects of IP3 on the MDM2-p53 complex in SA1 cells. In order to detect the p53-MDM2 complex, SA1 cells extracts were immunoprecipitated with MDM2 speci®c antibodies (2A10) and the levels of coprecipitating p53 were measured by Western blotting (Figure 2a ). p53 was detected in the immunoprecipi- ) were transfected with 3 mg DNA (pcDNA3 vector) and selected with G418 as described in Materials and methods. The results are the average of three plates in two separate experiments Figure 2 Eects of IP3.2 on the MDM2-p53 complex in SA1 cells. (a) The MDM2-p53 complex is detectable in SA1 cell extracts. Extracts (250 mg) were immunoprecipitated with the anti-MDM2 antibody 2A10 (step 1) and the depleted cell extracts were re-precipitated with the anti-p53 antibody 421 (step 2). The original extracts (EXT., STEP 0, lane 1), the supernatants after immunodepletion (SUP., STEPS 1, 2; lanes 2 and 3), and the immunoprecipitates (PPT., lanes 4 and 5) were analysed by 9% SDS ± PAGE and blotted. The membranes were cut and the upper part incubated with anti-MDM2 antibodies (2A10 + SMP14 + IF2) and the lower part with anti-p53 (DO1). The arrows indicate the MDM2 and p53 speci®c bands. (b) IP3.2 and IP3 speci®cally interact with MDM2. SA1 cells were transfected with expression vectors (10 mg/9 cm plates) for GST (CON, lanes 1 and 2), GST-IP3 (IP3, lanes 3 and 4), GST-IP3.2 (IP3.2, lanes 5 and 6) and GST-mIP3 (mIP3, lanes 7 and 8) and 24 h later cell extracts (250 mg) were incubated with glutathione-Sepharose beads. The original cell extracts (LOAD) and the retained fractions (BEADS) were analysed by 9% SDS ± PAGE and Western blotting. The relevant portions of the membranes were incubated with antibodies against MDM2 (2A10 + SMP14 + IF2), p53 (DO1 + 421 + 240) and GST (1D10). The speci®c bands are indicated. (c) Decrease in the amount of p53 complexed to MDM2 in cells expressing GST-IP3.2. SA1 cells were transfected with expression vectors (10 mg/ 9 cm plate) for GST (CON., lanes 1 and 3) and GST-IP3.2 (IP3.2, lanes 2 and 4) and 12 h later cell extracts were immunoprecipitated with anti-MDM2 antibodies (2A10). The original cell extracts (EXT., lanes 1 and 2) and the immunoprecipitates (PPT., lanes 3 and 4) were analysed by 9% SDS ± PAGE and Western blotting. tates (lane 4), but not in control immunoprecipitates using non-speci®c antibodies against either GST or Gal4 (data not shown). The MDM2 antibody depleted extracts were re-immunoprecipitated with p53 speci®c antibodies (421) to detect free p53. The second immunoprecipitate (STEP 2) contained a large amount of p53 and no detectable MDM2 (lane 5). About 10 times more p53 was found in the second precipitates (compare lanes 4 and 5). The immunoprecipitations were complete, since, compared to the original extracts (lane 1), the MDM2 depleted extract lacked detectable MDM2 (lane 2) and the extract further depleted of p53 lacked detectable p53 (lane 3).
The immunoprecipitation results were highly reproducible. Similar results were obtained with dierent preparations of 2A10 antibodies, with another anti-MDM2 antibody (SMP14) and using [
35 S]methionine and -cysteine metabolically labelled cell extracts. Furthermore, the proportion of p53 in the complex was the same in less stringent wash conditions. As expected, in the converse experiments, using p53 antibodies ®rst, most of the MDM2 was found to be free of p53 (data not shown). These results show that SA1 cell extracts contain detectable levels of the MDM2-p53 complex, even though most of the p53 is apparently not in this complex. The presence of free p53 could account for the relatively high transcriptional activity in these cells (Table 1) .
We would predict, from the work of Lane and collaborators (Bottger et al., 1996) , that IP3 expressed in SA1 would form a complex with MDM2 and that p53 would be absent from this complex. The GST proteins were expressed in SA1 cells by transient transfection, isolated with glutathionine-Sepharose beads and analysed by SDS ± PAGE and Western blotting ( Figure 2b ). The levels of expressed GST served as a control of transfection eciency and the comparison of 5 5load4 4 and 5 5beads4 4 as a measure of the eciency of retention on beads. There were relatively high levels of MDM2 associated with GST-IP3.2 (lane 6), lower levels with GST-IP3 (lane 4, the MDM2 band was clearly visible on the original a Inhibition of p53 interactions with MDM2 C Wasylyk et al autoradiogram), further diminished levels with GSTmIP3 (lane 8) and no detectable MDM2 with GST (lane 2). p53 was not detectably associated with any of the GST proteins (lanes 2, 4, 6 and 8). These results indicate that in SA1 cells GST-IP3.2 interacts with MDM2, and that the order of anities is GST-IP3.24GST-IP34GST-mIP344GST. p53 is not detectably associated with the complex. We investigated whether GST-IP3 expression inhibited MDM2-p53 complex formation in SA1 cells. GST and GST-IP3.2 were expressed by transient transfection. Control transfections with a GFP expression vector showed that about 60% of the cells had been transfected (data not shown). Twelve hours after removing the precipitate cell extracts were prepared, immunoprecipitated with anti-MDM2 antibodies and analysed by Western blotting (Figure 2c ). GST-IP3.2 transfected cells reproducible contained less p53 complexed to MDM2 (lane 4) than the controls with GST (lane 3), whereas the untreated cell extracts had equivalent levels of p53 (lanes 1 and 2). The relative levels of MDM2 in the extracts and the immunoprecipitates, as well as to a certain extent a non-speci®c band (*) served as controls for recovery. These results indicate that IP3-dimer inhibits MDM2-p53 complex formation in vivo in SA1 cells.
We further investigated the properties of IP3-dimer by studying its cellular localisation and its eects on the levels and localisation of MDM2 and p53, as well as cell morphology. GST and GST-IP3 were expressed in SA1 cells and 24 h later the cells were stained with antibodies against GST, MDM2 or b Figure 3 Cellular localisation of GST and GST-IP3.2. SA1 cells were transfected with expression vectors (1 mg/well of a six well CLUSTER plate containing a glass coverslip) for GST (CONTROL) and GST-IP3.2 (IP3.2). Twenty-four hours later the cells were ®xed with acetone/methanol and analysed by immunocytochemistry with antibodies against GST (1D10), MDM2 (2A10) and p53 (DO1) followed by Texas-Red conjugated goat anti-mouse and Hoechst to detect nuclei. The cells were visualised with ā uorescence microscope and photographed. The antibody, Hoechst and combined images are shown. Arrowheads indicate cells that appear to be in various stages of apoptosis p53, and Texas-Red secondary antibodies, followed by immuno¯uorescence microscopy ( Figure 3 and data not shown). In the control transfections, GST was detected in about 20% of the cells, and was localised throughout the cell (compare the panels with antibody, Hoechst staining of nucleic and the combined images). The proportion of positive cells was consistently lower than with GFP, due to the relatively low eciency of the GST antibodies. Endogenous MDM2 was found predominantly in the nucleus and at a similar level in the majority of cells (the selected ®eld in the ®gure was chosen to show one rare brighter cell to emphasise the nuclear localisation). p53 was distributed throughout the cell. The GST-IP3.2 transfected cells were strikingly dierent, with about 20% or more of the cells with the following clearly altered characteristics (Figure 3 and data not shown). GST-IP3.2 was localised predominantly in the nuclei. MDM2 staining was much brighter in the nuclei compared to the controls. p53 staining was predominantly nuclear and clearly enhanced. Many of the positive cells had unusual morphology compared with the control, with missshaped, multi-lobular and shrunken nucleic (see arrowheads), suggestive of apoptosis. Furthermore, there were also shrunken multi-lobular nucleic that were negative for GST-IP3.2, which could be late apoptotic cells in which GST expression could no longer be detected. These results suggest that GST-IP3.2 is recruited to the nucleus by interactions with MDM2, where it alters the levels and activities of p53 and MDM2 and other factors. We investigated these possibilities in a number of assays.
Transfection experiments in SA1 cells with a p53 reporter (MDM2-luc) showed that p53 activity was increased by expression of IP3, and to a greater extent by IP3-dimer, but not by either the mutant peptide or the control vector (Figure 4) . In MCF7 cells, expression of either IP3 or IP3-dimer stimulated p53 activity, whereas the mutant and the control had no eect. Expression of the monomer was sucient to achieve near maximum activation, in keeping with the lower level of MDM2 in MCF7 cells. There was a small (about 1.5-fold) eect in CASKI, and no detectable eect in HeLa and HSC2, in keeping with the lower levels or absence of MDM2 and p53 in these cells.
We investigated the eects of IP3 in SA1 cells on the expression of endogenous p53 regulated genes, mdm2 and p21. Cells were transfected with expression vectors and, after 24 h, RNA was quantitated by RNAase protection and protein by Western blotting. The RNAse protection assay quantitates RNA transcribed from the two mdm2 promoters, the constitutive P1 promoter and the p53 dependent P2 promoter (Juven et al., 1993; Wu et al., 1993; Zauberman et al., 1995; Landers et al., 1997) . The house-keeping gene, glyceraldehyde 3 phosphate dehydrogenase (G3PDH), serves as a control for loading. Transfection eciencies in this experiment were about 50%, as estimated by transfecting an expression vector for the green uorescent protein (GFP) and counting¯uorescent cells. Transcription from the P2 promoter was stimulated about fourfold by IP3-dimer ( Figure 5 , lanes 1 and 2; quantitated by scanning and correction for the internal control, but without adjustment for the proportion of cells that are transfected). The mutant peptide with reduced anity for MDM2 had a much smaller eect (less than 1.5-fold, lane 3). E6 expression Figure 4 Eect of GST-IP3 on p53 activity in dierent cell lines. Cells were transfected with 1 mg MDM2-Luc, 0.2 or 1 mg of the indicated expression vectors [pBC-IP3, pBC-IP3.2, pBC-mIP3, or pBC (C, control)], 1 mg pSG5-lacZ (total 5 mg, made up with pEMBL, six well CLUSTER plates, 2.5 ml medium + 10% FCS). After 24 h, luciferase and b-galactosidase activities were measured. Corrected luciferase activities, relative to the basal level with control vector, are plotted. The dierences between duplicates were on average 5% and one representative experiment is shown Figure 5 Eect of IP3.2 on RNA expression from the human mdm2 gene. SA1 cells were transfected with 5 mg of expression vectors for GST (pBC, control, lanes 1 and 4), GST-IP3.2 (pBC-IP3.2, lanes 2 and 5), GST-mIP3 (pBC-mIP3, lane 3), E6 (pTL2-E6, lanes 4 and 5), and 5 mg of the empty vector for E6 (pTL2, lanes 1 ± 3) and after 24 h RNA was extracted and 5 mg was analysed by RNAase protection to detect RNA initiated from the P1 and P2 promoters of the mdm2 gene and RNA transcribed from the control house-keeping gene, glyceraldehyde 3-phosphate dehydrogenase (G3PDH). Lane 6: complete reaction with tRNA in the place of cellular RNA. Lane 7: one-tenth of incubation without RNAase treatment. FL: full length inhibited both basal and IP3-dimer induced P2 transcription to below the basal level (0.6 and 0.7, respectively, compare lanes 4 and 5 with 1), as expected from the ability of E6 to degrade p53. There was no signi®cant eect of the expressed proteins on transcription from the P1 promoter (lanes 1 ± 5; 1+0.2, taking into account the loading control, G3PDH). At the protein level, GST was used to control for transfection eciency and TBP for loading (Figure 6 ). IP3-dimer increased MDM2 protein levels about sevenfold (lanes  1 and 2) . The greater increase in MDM2 protein compared to RNA is expected, since IP3 speci®cally stimulates synthesis of P2 promoter RNA, which is translated more eciently (Barak et al., 1994; Landers et al., 1994 Landers et al., , 1997 . MDM2 levels did not increase: (1) in the presence of the mutant peptide, showing that the eect was speci®c, and (2), when E6 was co-expressed with IP3-dimer (lanes 4 and 5), showing that the eect was p53 dependent. IP3-dimer increased p53 levels about threefold in a speci®c manner (compare lane 2 with 1, 3 ± 5), as expected from the release from MDM2 mediated degradation (Haupt et al., 1997; Kubbutat et al., 1997) . We also studied the eects on expression of p21, another p53 regulated gene. Similar to MDM2, IP3-dimer increased p21 levels, the mutant peptide had no eect and E6 blocked the increase due to IP3-dimer. However, MDM2 levels increased more than p21 in response to IP3-dimer. In conclusion, IP3 stimulates MDM2 and p21 expression in a p53 dependent manner.
The eects of IP3 on cellular physiology was studied by a number of assays: colony formation, cell cycle analysis, and TUNEL. In the colony forming assay (Table 3) , compared to the control vector (pBC) and the mutant peptide (pBC-mIP3), expression of IP3 (pBC-IP3) decreased colony formation about ninefold. We also investigated the eects of down-regulating MDM2 levels using antisense RNA. Expression of human mdm2 RNA from the CMV promoter decreased colony formation more than fourfold (Table 3 , note that the selectable markers are expressed in dierent ways in the pBC and pCMV experiments, which accounts for the dierence in number of colonies in the control). For cell cycle analysis, CD20 expression was used to label transfected SA1 cells. Thirty-six hours after transfection the cells were harvested, permeabilised, stained with propidium iodide to label DNA and uorescein conjugated anti-CD20 to identify transfected cells, and analysed by FACS to quantitate the sub-G1, G0/G1, S and G2/M populations of transfected cells. The results are presented as the change in cell cycle distribution compared to the control vectors (pBC for pBC-IP3 and pBC-mIP3, pCMV for pCMV-AS-mdm2 and pCDNA3 for CTS1). Thirty-six hours was found to be the optimum time point for the analysis, from FACS SCAN analyses performed at dierent times. The results at the other time points are entirely consistent with the conclusions from the analyses at 36 h (data not shown). The results were similar whether the comparisons were made between transfected cells in the test and control transfections, or between the transfected and nontransfected populations in the same sample. The average of three independent experiments is presented (Figure 7 ). IP3 expression resulted in an increase in the number of cells with sub-G1 and G0/G1 contents of DNA and a decrease of those in S and G2/M (Figure 7 , IP3). The mutant peptide (mIP3) had a much diminished eect. Anti-sense mdm2 RNA qualitatively had a similar eect as IP3, increasing the sub-G1 and G0/G1 populations and decreasing S and G2/M. However, quantitatively, the eect was dierent, raising the possibility that the eects of IP3 and antisense may not be strictly equivalent. As expected, the control, CTS1, also increased sub-G1 and G0/G1 populations relative to S and G2/M.
In a third approach, a ®xed number of cells (200) were microinjected with IP3 and GFP expression vectors and, at various times, surviving cells were Figure 6 Eect of IP3.2 on MDM2, p53 and p21 protein levels. SA1 cells were transfected with 5 mg of expression vectors for GST (pBC, control, lanes 1 and 4), GST-IP3.2 (pBC-IP3.2, lanes 2 and 5), GST-mIP3 (pBC-mIP3, lane 3), E6 (pTL2-E6, lanes 4 and 5), and 5 mg of the empty vector for E6 (pTL2, lanes 1 ± 3) and after 24 h protein was extracted and 20 mg was analysed by 8 or 12% SDS ± PAGE, blotted on nitrocellulose membranes and probed with antibodies against MDM2 (IF2), p53 (DO1), p21 (IWA1C5), GST (ID10) and TBP (3G3), followed by ECL (Amersham) SA1 cells (5610 5 ) were transfected with either: (1) 0.5 mg pGKneo and 10 mg expression vectors for GST (pBC), GST-mIP3 (pBC-mIP3) and GST-IP3 (pBC-IP3) or (2) 1 mg pCMV neo Bam (pCMV EMPTY) or pCMV-AS-mdm2. Stably transformed cells were selected with G418. The results are the average of three plates in two independent experiments identi®ed by expression of GFP and apoptotic cells by the TUNEL assay (Table 4 , note that the cells were not exposed to UV at any time before analysis, to avoid any potential synergy with IP3 in the induction of apoptosis). The number of GFP positive cells was 132 after 18 h, 77 after 24 h and 0 after 48 h. There was an increase in cell debris corresponding to the loss of GFP positive cells, indicating that the injected cells were dying. In the control cells with the mutant peptide, the number of GFP positive cells remained relatively constant, showing that the decrease was not a nonspeci®c eect due to injection. The number of TUNEL/ GFP positive cells in the IP3 injection was 11 after 18 h, 25 after 24 h and 0 after 48 h. In contrast, with the mutant peptide, there was 5, 6 and 30, respectively. These results indicate that IP3 expression is speci®c and results in extensive cell death. Not all of the cells were TUNEL positive at any particular time point, suggesting that apoptosis was not synchronous. The results were similar when an anti-sense mdm2 expression vector was injected. After 24 h there were 67 GFP positive cells, 15 of which were TUNEL positive, and, after 48 h, the number of positive cells decreased to 20 with many dead cells, and there were no TUNEL positive. With the control vector the number of GFP positive cells did not decrease, there were 80 and 127 after 18 and 48 h, respectively, and there were few TUNEL positive cells, two and ®ve respectively. Taken together, these results show that disrupting MDM2-p53 interactions in SA1 cells leads to inhibition of colony formation, cell cycle arrest and cell death from apoptosis.
The eects of IP3 on colony formation and the cell cycle are p53 dependent
We investigated the role of p53 in the eects of IP3 on colony formation and the cell cycle. In the colony forming assay (Table 6 ), IP3-dimer gave about 14 clones per plate and E6 about 80. E6 overcame the eect of IP3-dimer, restoring colony formation to essentially the level with E6 alone. In cell cycle analysis (Figure 8 ), 36 h after transfection, IP3-dimer expression resulted in an increase in the sub-G1 population and a decrease in the combined S+G2+M population (note that there is a greater proportion of cells in the sub-G1 population than with IP3 monomer in Figure 7 , in keeping with the greater eciency of the dimer). E6 alone had little in¯uence on the cell cycle and largely neutralised the eect of IP3-dimer. These results show that the eect of IP3 on colony formation and the cell cycle are p53 dependent.
IP3 inhibits E2F activity in a p53 dependent manner
The N-terminal region of MDM2 interacts with E2F1 and DP1 (Martin et al., 1995) , components of the E2F family of factors (Bernards, 1997; Johnson and Schneider-Broussard, 1998) , raising the possibility that IP3 may also aect E2F activity. We followed E2F activity using an E2F-CAT reporter in SA1 and MCF7 cells in low serum conditions. In SA1 cells, E1A expression stimulated E2F activity up to twofold (E1A, Figure 9 ), whereas serum had no eect (HS), showing that E2F is highly active and cannot be stimulated much further by activators of E2F (Bernards, 1997; Johnson and Schneider-Broussard, 1998 ). IP3-dimer Figure 7 Eect of IP3 and antisense mdm2 on the cell cycle. SA1 cells were transfected with 5 mg pCMV-CD20 and 15 mg of either pBC, pBC-IP3, pBC-mIP3, pCMV, pCMV-AS-mdm2, pcDNA3 or pcDNA3-CTS1. After 36 h the cells were harvested, processed and analysed by FACS. A total of 10 000 CD20 positive cells were analysed for DNA content. The results are presented as the per cent change in the proportion of cells with various DNA contents (sub-G1, G0/G1, S, G2/M) relative to the transfections with empty vector. The cell cycle distributions for the controls (pBC, pCMV neo Bam, pCDNA3) were: 8+2% sub-G1, 47+3% G0/G1, 14+2% S 31+3% G2/M. The results are the average of two independent transfections in three dierent experiments One hundred SA1 cells were microinjected with a mixture of pcDNA3-GFP and empty (pCMV) or antisense mdm2 (pCMV-ASmdm2) and stained for TUNEL 18 or 48 h later as described in Materials and methods. GFP and GFP/TUNEL positive cells were scored The eects of IP3 on E2F activity could be direct (Martin et al., 1995) , or indirect through p53 and its eects on the cell cycle. To investigate these possibilities we repeated the experiment using E6 to inhibit p53 activity (Figure 10) . In control experiments, using a p53 reporter (MDM2-luc), E6 expression was found to eciently inhibit both basal and IP3 induced p53 activity, in both SA1 (Figure 10a ) and MCF7 (Figure 10b ) cells. In SA1 cells, E6 expression had a slight positive eect on endogenous E2F activity and overcame IP3 induced inhibition of E2F activity. Mutant p53 (H175), that can inhibit wild-type p53 in a transdominant manner, had a similar eect as E6 (data not shown). This result helps to exclude that the eect of E6 is indirect, through an unexpected eect on the IP3/MDM2 complex. The results were similar in MCF7 cells. E6 has a small positive eect on endogenous E2F activity and eciently blocked IP3 mediated inhibition. Mutant p53 also overcame IP3 inhibition of E2F activity (data not shown). The release from IP3 inhibition was not total, raising the possibility of a relatively smaller p53 independent eect of IP3 on E2F activity in MCF7 cells. Variations in cell survival resulting from inhibition of cell death by E6 or mutant p53 cannot account for these results, since the variations in E2F activity were seen early, before the appearance of apoptotic cells, and there were no eects on several control reporters lacking E2F responsive elements (b-galactosidase internal control and data not shown). These results show that IP3 inhibits E2F activity in a predominantly p53 dependent manner.
Discussion
We have used a tagged peptide to investigate the eects of blocking p53-MDM2 interactions in vivo. Studies of p53 interactions with MDM2 have led to the isolation of novel MDM2 binding peptides, such as IP3, whose sequence resemble p53 but have up to a 100-fold higher anity for MDM2 than the equivalent p53 sequence (Bottger et al., 1996) . We used chimeric proteins, consisting of GST fused to either IP3, a dimer of IP3 or a mutant peptide with alanine substitutions of critical amino acids for MDM2 interaction (Bottger et al., 1996) . GST was chosen because it is frequently used as a`tag' and has no known non-speci®c eects in the cell (Chatton et al., 1995) . We found that both the monomer and the dimer had speci®c eects on p53 activity, the cell cycle and cell survival. The eects were speci®c, since they were not observed with the controls (mutant peptide, GST alone and empty vector). Furthermore, there was no eect in HSC2 cells lacking a p53-MDM2 complex (results and data not shown). In contrast, the use of a homeo-derived peptide-IP3 fusion protein that can translocate across biological membranes (Brugidou et al., 1995) was less Figure 8 Eect of HPV16 E6 and IP3.2 on the cell cycle. SA1 cells were transfected with expression vectors for GST-IP3.2 (7.5 mg), HPV16 E6 (7.5 mg), or both, as indicated, and 5 mg CD20. After 36 h the cells were harvested, processed for FACS analysis of DNA content (sub-G1, G0/G1, S/G2/M combined) of CD20 positive transfected cells. The results are presented as the per cent change in proportion of cells with various DNA contents relative to the transfection with empty vectors. The cell cycle distribution for the control with empty vectors was 8+2% sub-G1, 47+3% G0/G1, 45+4% S/G2/M. The results are the average of two independent transfections in two dierent experiments Figure 9 Eect of IP3 on E2F activity. SA1 and MCF7 cells were transfected with 1 mg E2F-CAT reporter, 0.2 and 1 mg expression vectors for EIA (EIA-SV), GST-IP3.2 (pBC-IP3.2) and its control (pBC) and 1 mg internal control (pSG5-LacZ). After transfection, the cells were incubated in medium with either 10% FCS (high serum, HS) or 0.5% FCS (low serum) and CAT and b-galactosidase activity were determined 24 h later. CAT activity was adjusted for b-galactosidase activity to correct for variations in transfections eciency, and plotted as activity relative to the basal level in the presence of control vector (pSG5, CON). The dierence between duplicates was on average 5% successful, due to the toxicity of the homeo-derived peptide alone. The dimer provides two binding sites for MDM2, and, as predicted, turned out to be more ecient than the monomer. Whilst this work was in progress, BoÈ ttger et al. (1997) reported the eects of a synthetic MDM2 binding mini protein (super TIP) in which the same peptide is displayed on the active site loop of thioredoxin. Super TIP expression in MCF7 cells induced a threefold increase in p53 activity and cell cycle arrest, similar to our ®ndings (results and data not shown). However, super TIP was relatively inecient in inducing p53 activity in SA1 cells (BoÈ ttger et al., 1997), whereas we observed stronger activation than in MCF7. There are a number of possibilities to explain why GST-IP3 is more ecient than super TIP. One possibility is cellular localisation, since nuclear ± cytoplasmic shuttling of MDM2 has been shown to regulate p53 levels (Roth et al., 1998) . We have shown that, whereas GST is found throughout the cell, GST-IP3.2 is found in nuclear structures, consistent with it being recruited to the nucleus by interactions with MDM2. A critical cellular parameter that can aect the eciency of an inhibitor is the position of the equilibrium between MDM2 and p53.
The MDM2-p53 autoregulatory loop can be considered to be set at dierent levels, depending upon the signalling inputs to p53 and MDM2. Various mechanisms that regulate p53 have been established, whereas those that regulate MDM2 are more poorly understood. Mdm2 RNA is expressed at dierent levels in mouse tissues during embryogenesis and the pattern is essentially the same in p53 null mice (LeÂ veillard et al., 1998) , showing that there are factors besides p53 that control mdm2 expression. Basic FGF induces MDM2 levels in ®broblasts in culture (Shaulian et al., 1997) . One extreme of the equilibrium, MDM2 in the absence of p53, is found in p53 null mice and cell lines such as HSC2, whereas the other extreme, wild-type p53 in the absence of MDM2 is lethal (Montes de Oca Luna et al., 1995; Jones et al., 1995) . In SA1 cell, with high levels of MDM2 due to gene ampli®ed, the equilibrium is expected to be shifted towards particularly low levels of p53. In MCF7 cells, with high levels of wild-type p53, the level of MDM2 expression is lower and presumably mainly driven by p53. However, the absolute levels of MDM2 and p53 are not sucient to judge the setting of the equilibrium, since Figure 10 Eects of HPV16 E6 and IP3 on E2F activity. SA1 and MCF7 cells were transfected with 1 mg E2F-CAT reporter or 1 mg MDM2-Luc reporter, 0.2 and 1 mg expression vectors for GST (pBC), GST-IP3 (pBC-IP3), E6 (pTL2-E6) and 1 mg internal control (pSG5-LacZ). Control vectors for E6 (pTL2) and GST-IP3 (pBC) were added to the transfections to keep the amount of each expression vector constant. CON: empty vectors alone. The cells were incubated in medium with 0.5% FCS and after 24 h luciferase, CAT and b-galactosidase activity were measured. CAT and luciferase activities were adjusted for b-galactosidase activity to correct for variations in transfection eciency, and plotted as activity relative to the basal level in the presence of control vectors (CON). The dierence between duplicates was on average 5% phosphorylation of both MDM2 (Mayo et al., 1997) , and p53 (Shieh et al., 1997) can inhibit complex formation. Furthermore, the tumour suppressor p19 ARF participates in the regulatory loop by binding to both factors, and stabilising and activating p53 Pomerantz et al., 1998; Stott et al., 1998; de Stanchina et al., 1998; Zindy et al., 1998; Kamijo et al., 1998) . A simple interpretation of our results is that the greater eect of IP3 on p53 transcriptional activity in SA1 compared to MCF7 results from the higher level of MDM2 and consequent greater inhibition of p53 in SA1 cells. However, despite the high levels of MDM2 and the lower levels of p53 in SA1 cells, the majority of the p53 is not complexed to MDM2. In MCF7 cells, that contain a relatively higher ratio of p53 to MDM2, we also ®nd that most of the p53 is not complexed to MDM2 (data not shown). It remains to be seen whether the free p53 contributes to the eects of the p53 released by IP3 from MDM2.
The increase in p53 activity in SA1 cells is accompanied by an increase in p53 protein levels essentially in the nucleus, as expected from release from MDM2 mediated degradation and blocking of nuclear export of p53 by MDM2 (Haupt et al., 1997; Kubbutat et al., 1997; Bottger et al., 1997; Roth et al., 1998) . There is a p53 dependent increase in transcription from the p53 dependent P2 promoter of the endogenous mdm2 gene, and no signi®cant eect upon the constitutive P1 promoter. There is a greater increase in MDM2 protein compared to RNA, as expected from the preferential increase in RNA initiated from the P2 promoter and its greater translation eciency (Barak et al., 1994; Landers et al., 1994 Landers et al., , 1997 . There is also an increase in p21, that is smaller than MDM2, in keeping with the greater copy number of the mdm2 gene. It is interesting that, despite the large increase in MDM2, that would tend to titrate out IP3, there is a sucient amount of the inhibitor to trigger p53 dependent cell cycle arrest and cell death. Cell cycle arrest is the expected eect of p21 induction by p53. Cell death is predictable from the loss of the restraining eects of MDM2 on the apoptotic function of p53 (Kondo et al., 1995; Chen et al., 1996; Haupt et al., 1996) . MDM2 has p53 independent functions which could have contributed to the eects of IP3. The Nterminal region of MDM2 has been reported to interact with two E2F factors, E2F1 and DP1 (Martin et al., 1995) . MDM2 also interacts with pRb (Xiao et al., 1995) , a regulator of E2F activity. These interactions do not appear to directly contribute to the eects of IP3, since they are p53 dependent. The role of p53 in E2F regulation could be indirect, through induction of p21 and cell cycle arrest. There is also the possibility of a direct link, because E2F1 and DP1 have been shown to bind directly to p53 and regulate its activity (O'Connor et al., 1995; Sorensen et al., 1996) . However, these interactions have been reported to be insensitive to MDM2. E2F1 regulates apoptosis by both p53 dependent (Kowalik et al., 1995 (Kowalik et al., , 1998 Qin et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994) and independent (Hsieh et al., 1997; Phillips et al., 1997) mechanisms. E2F1 is presumably not involved in apoptosis induced by IP3, since increased E2F activity is associated with apoptosis, whereas IP3 induces a decrease in E2F activity.
Several studies have used antisense strategies to determine the role of MDM2, either in proliferation and survival of multiple myeloma cells (Teoh et al., 1997) , or synergistic activation of p53 by inhibition of MDM2 expression and DNA damage . These experiments do not exclude that downregulation of MDM2 levels could aect p53 independent functions attributable to other parts of MDM2. Our studies support the proposal that small molecular inhibitors of p53-MDM2 interactions would provide a rational therapy for the treatment of tumours (Oliner et al., 1993; Picksley et al., 1996; Blaydes et al., 1997) . It is particularly encouraging that inhibition results in ecient cell death in cells in which MDM2 is highly over-expressed.
Materials and methods
Recombinants pBC-IP3.2, IP3, mIP3 Oligonucleotides coding for IP3, IP3-dimer (IP3.2) and mutant IP3 (mIP3) were cloned between the NdeI and BamHI of pBC (Chatton et al., 1995) . The amino acid sequences fused to the GST protein encoded by pBC are: IP3: MPRFMDYWEGLN; IP3.2: MPRFMDYWEGLNGPGMPRFMDYWEGLN; mIP3; MPRAMDYAEGAN. The oligonucleotide sequences are available on request.
pCMV-AS-mdm2 human mdm2 cDNA from B Vogelstein in pCMV neo Bam in the inverted orientation relative to the promoter.
MDM2-luc a gift from M Oren, containing the mouse mdm2 gene p53 responsive promoter (Juven et al., 1993) in pGL2 basic.
WAF1-luc a gift from B Vogelstein (el-Deiry et al., 1993) .
pCON, pGUP a gift from J Shay (Funk et al., 1992) . pSG5-lacZ from the IGBMC common facility. pCMVCD20 a gift from L Zhu (Zhu et al., 1993) .
pBLCAT2-3xWT (E2F-CAT) a gift from N La Thangue (Zamanian and La Thangue, 1992) . (Wasylyk et al., 1988) .
EIA-SV
pTL2-E6 HPV16 E6 coding sequences in pTL2.
pcDNA3-GFP GFP from pGFP-C1 (Clontech) in pcDNA3 vector (Invitrogen).
pGKneo from the IGBMC common facility.
CTS1, pcDNA3-p53 (Conseiller et al., 1998) .
Cell lines SA1 a gift from S Nooner and D Shapiro, formally OsA-CL (Oliner et al., 1992) .
MCF7, CASKI, HeLa from ATCC.
HSC2 a gift from N Tsuchida (Sakai and Tsuchida, 1992) .
Western blotting
Protein extraction, SDS ± PAGE, Western blotting and antibodies were as described previously (LeÂ veillard and Wasylyk, 1997).
Transfections
Cells were transfected by either the lipofectamine (Gibco ± BRL) or the calcium phosphate techniques and analysed for chloramphenicol acetyl transferase (CAT), luciferase (luc) and b-galactosidase (b-gal) as described previously (Conseiller et al., 1998; Wasylyk et al., 1997) . Luc and CAT values were corrected for b-galactosidase activity, to compensate for variations in transfection eciency. Individual samples were transfected in duplicate, and the experiments were repeated at least three times.
RNAase protection
Probes were generated by amplifying JAR cell cDNA with primers corresponding to exons 2 ± 3 of mdm2 and G3PDH. A second round of PCR was used to introduce the T7 polymerase promoter. First round primers for mdm2: 829, 5'-CAGTGGCGATTGGAGGGTAG-3' and 451L, 5'-GGCCGCGGGTGTCTTTTTGTGCACC-3'. Second round primers for mdm2 and G3PDH: 829 and T7L, 5' -GAGAATTCTAATACGACTCACTATAG GGCCGCGG-3'. First round primers for G3PDH: 151 5'-GTTGCCAT-CAATGACCCCTTC-3', 240L, 5'-GGCCGCGGGACGGTG-CCATGGAATT-3'. Overlapping linker sequences are in smaller type and the T7 promoter is underlined. RNAase protection assays were according to standard protocols, essentially as described by Landers et al. (1997) . The expected lengths in bases of the products for RNA initiated at the P1 and P2 promoters are 144 and 208, and for G3PDH 89.
FACS analysis
FACS analysis was as described previously (Dubs-Poterszman et al., 1995).
Microinjection and TUNEL staining
SA1 cells were seeded onto Cellocate 1 coverslips (Eppendorf). The plasmids were microinjected in the nucleus (0.3 mg/ml) along with pcDNA3-GFP (0.1 mg/ml) as a marker. Cells were ®xed in 4% formaldehyde, permeabilized in 0.2% Triton X-100 and blocked in Power Block 1 (BioGenex). Apoptotic cells were stained by incorporation of FITC-conjugated dUTP into DNA breaks using the`in situ cell death detection kit' (Boehringer).
Stable transfections
Forty-eight hours after transfection cells were seeded in 9-cm plates and cultured in 1 mg/ml G418 containing medium for 2 ± 3 weeks and then coloured with Geimsa. Transfections were done in duplicate and the experiments were repeated at least two times.
Immuno¯uorescence
Cells were cultured on cover slips and transfected as described above. After three washes with PBS, cells were ®xed in 50% acetone+50% methanol for 20 min at 7208C, saturated for 40 min in PBS+3% BSA at room temperature, incubated for 60 min with primary antibodies (1/500) at 378C, washed three times for 10 min with PBS, incubated for 60 min at 378C with the Texas-Red goat anti-mouse (Jackson) diluted 1/250 in PBS+0.5 mg/ml BSA and washed three times for 10 min in PBS. The cover-slips were incubated for 1 min at room temperature in Hoechst dye (5 mg/ml in PBS), washed three times in PBS and mounted by inversion on a drop of mounting solution (80% glycerol, 20% 16PBS with 5% propylgallate) on a glass slide. Slides were stored in the dark at 48C and visualised under a¯uorescence microscope.
Immunoprecipitation
Immunoprecipitations were performed by standard techniques established for the study of the p53-MDM2 complex (Momand et al., 1992; Momand and Zambetti, 1996; Hinds et al., 1987) . Cells were either lysed directly on the plate or by freeze thaw followed by soni®cation, with essentially identical results. Five hundred mg cell extracts (BioRad protein assay) at 48C were pre-absorbed with 50 ml of a 50% suspension of protein G-Sepharose, incubated for 1.5 h with the primary antibody (generally 1 ml acites, initially titrated to optimise conditions; anti-MDM2: 2A10 and SMP14; anti-p53: 421; controls: anti-GST 1D10 and anti-Gal4 3GV3) followed by 1.5 h with protein GSepharose, and then washed four times for 5 min with SNNTE buer (IP buer gave essential similar results). The pellets were suspended in loading buer and analysed by SDS ± PAGE and Western blotting. The secondary antibodies for the MDM2 and GST blots were horseradish-peroxidase conjugated goat anti-mouse (Jackson) and for p53 horseradish-peroxidase conjugated goat antimouse kappa (k). In the GST pull down assay glutathioneSepharose replaced the antibodies and protein G-Sepharose. The incubation conditions and buers were the same as for immunoprecipitation or as described (Maira et al., 1996; Chatton et al., 1995) , with essentially identical results.
